DALLAS, June 16, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc. (Nasdaq:MIPI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/MIPI
Molecular Insight Pharmaceuticals Inc. (MIPI), a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. The Company has five clinical-stage candidates in development. Its lead oncology product candidates include Azedra, Onalta, Trofex and Solazed. Azedra and Onalta are being developed for the treatment of neuroendocrine cancers; Trofex is being developed for the detection of metastatic prostate cancer, and Solazed is being developed for the treatment of metastatic melanoma. Its non-oncology product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia (insufficient blood flow to the heart muscle).
Message Board Search for MIPI: http://www.boardcentral.com/boards/MIPI
In the report, the analyst notes:
"MIPI last week released a press release noting its presentation at the Nuclear Medicine 2010 meeting in Salt Lake City. The Company said it presented nonclinical data demonstrating the utility of its novel radiopharmaceutical compounds for the molecular imaging of prostate and other tumors.
"MIPI also announced the receipt of SNM's 2010 Berson-Yalow Award for a nonclinical study demonstrating the potential of the Company's compound 99mTc-MIP-1340 to provide accurate imaging of metastatic prostate cancer. The Berson-Yalow Award honors originality and research that makes the most significant contributions to basic or clinical radioassay science."
To read the entire report visit: www.microstockprofit.com/lp/MIPI.
See what investors are saying about MIPI at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com.
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.